{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T10:59:17Z","timestamp":1786273157711,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11904-018-0398-8","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T21:36:14Z","timestamp":1530567374000},"page":"293-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Federal Response to the Opioid Crisis"],"prefix":"10.1007","volume":"15","author":[{"given":"Kimberly","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"398_CR1","unstructured":"\u2022\u2022 Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 2017. Retrieved from \n                      https:\/\/www.samhsa.gov\/data\/\n                      \n                    . Current epidemiologic data on opioid use, use disorder, and associated conditions."},{"key":"398_CR2","unstructured":"\u2022\u2022 Ahmad FB, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. Retrieved from \n                      https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm\n                      \n                    . Current overdose death data."},{"issue":"4","key":"398_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7326\/M14-2559","volume":"162","author":"R Chou","year":"2015","unstructured":"\u2022 Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain. Annals of Internal Medicine. 2015;162(4):276\u201386. Evidence of poor outcomes for use of opioids for chronic pain","journal-title":"Annals of Internal Medicine"},{"key":"398_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","volume":"169","author":"LT Wu","year":"2016","unstructured":"Wu LT, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016 Dec 1;169:117\u201327.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"398_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1377\/hlthaff.2015.1424","volume":"35","author":"MV Ronan","year":"2016","unstructured":"Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse\/dependence and associated serious infections increased sharply, 2002\u201312. Health Aff. 2016 May 1;35(5):832\u20137.","journal-title":"Health Aff"},{"issue":"10","key":"398_CR6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/cid\/ciu643","volume":"59","author":"AG Suryaprasad","year":"2014","unstructured":"Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012. Clin Infect Dis. 2014 Aug 11;59(10):1411\u20139.","journal-title":"Clin Infect Dis"},{"key":"398_CR7","unstructured":"\u2022 Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, Serrecchia J, Blankenship S, Ward JW, Holtzman D. Increases in hepatitis C virus infection related to injection drug use among persons aged \u2264 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR. Morb Mortal Wkly Rep 2015 May;64(17):453\u2013458."},{"key":"398_CR8","doi-asserted-by":"crossref","unstructured":"\u2022 Wejnert C. Vital signs: trends in HIV diagnoses, risk behaviors, and prevention among persons who inject drugs\u2014United States. MMWR. Morbidity and mortality weekly report. 2016; 65. Information on linkages between HIV trends and opioid use.","DOI":"10.15585\/mmwr.mm6547e1"},{"issue":"3","key":"398_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1515195","volume":"375","author":"PJ Peters","year":"2016","unstructured":"Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014\u20132015. N Engl J Med. 2016 Jul 21;375(3):229\u201339.","journal-title":"N Engl J Med"},{"key":"398_CR10","unstructured":"CDC. Enhanced state opioid overdose surveillance. Available at: \n                      https:\/\/www.cdc.gov\/drugoverdose\/foa\/state-opioid-mm.html\n                      \n                     Accessed November 21, 2017."},{"key":"398_CR11","unstructured":"CDC. National Syndromic Surveillance Program\u2014Biosense Platform and ESSENCE. Available at: \n                      https:\/\/www.cdc.gov\/nssp\/biosense\/index.html\n                      \n                     Accessed November 21, 2017."},{"key":"398_CR12","unstructured":"HIDTA\u2014OD Map. Real-time overdose surveillance data across jurisdictions to support public safety and health. \n                      http:\/\/www.hidta.org\/odmap\/\n                      \n                     Accessed December 6, 2017."},{"key":"398_CR13","unstructured":"Coughlin, B. Office of the Chief Technology Officer, HHS, Rapid Opioid Alert and Response: (ROAR) a new tool to address the opioid epidemic in local communities. Innovating in Government. 6\/20\/17 \n                      https:\/\/www.hhs.gov\/idealab\/2017\/06\/20\/rapid-opioid-alert-response-roar-a-new-tool-to-address-the-opioid-epidemic-in-local-communities\/\n                      \n                    ."},{"key":"398_CR14","unstructured":"Warner, M., Trinidad, J.P., Bastian, B.A., Mini\u00f1o, A.M. and Hedegaard, H., 2016. Drugs most frequently involved in drug overdose deaths: United States, 2010-2014. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 65(10), pp.1\u201315."},{"key":"398_CR15","unstructured":"\u2022 Williams AR, Nunes E, Olfson M. To battle the opioid overdose epidemic, deploy the \u201cCascade of Care\u201d model. Health Affairs Blog, March 13, 2017. Available at: \n                      https:\/\/www.healthaffairs.org\/action\/showDoPubSecure?doi=10.1377%2Fhblog20170313.059163&format=full\n                      \n                    . Accessed November 21, 2017. Proposed model of assessing the quality of the system of care in terms of access to care and use of evidence-based care for opioid use disorder."},{"issue":"8","key":"398_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jpain.2015.05.002","volume":"16","author":"RL Nahin","year":"2015","unstructured":"Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16(8):769\u201380.","journal-title":"J Pain"},{"issue":"15","key":"398_CR17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. JAMA. 2016 Apr 19;315(15):1624\u201345.","journal-title":"JAMA"},{"key":"398_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","volume":"66","author":"GP Guy","year":"2017","unstructured":"Guy GP. Vital signs: changes in opioid prescribing in the United States, 2006\u20132015. MMWR Morb Mortal Wkly Rep. 2017;66:697\u2013704.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"398_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2105\/AJPH.2012.301209","volume":"103","author":"R Spoth","year":"2013","unstructured":"Spoth R, Trudeau L, Shin C, Ralston E, Redmond C, Greenberg M, et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. AJPH. 2013;103:665\u201372.","journal-title":"AJPH"},{"issue":"9909","key":"398_CR20","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0140-6736(13)61686-4","volume":"382","author":"T McAfee","year":"2013","unstructured":"McAfee T, Davis KC, Alexander RL, Pechacek TF, Bunnell R. Effect of the first federally funded US antismoking national media campaign. Lancet. 2013;382(9909):2003\u201311.","journal-title":"Lancet"},{"issue":"2","key":"398_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015 Mar 1;23(2):63\u201375.","journal-title":"Harv Rev Psychiatry"},{"key":"398_CR22","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"\u2022\u2022 Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health (ajph). 2015 Aug 3;105:e55\u201363.","journal-title":"Am J Public Health (ajph)"},{"issue":"11","key":"398_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/jama.2016.10542","volume":"316","author":"BD Stein","year":"2016","unstructured":"Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211\u20132.","journal-title":"JAMA"},{"key":"398_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","volume":"78","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Dunn KE. Why aren't physicians prescribing more buprenorphine? J Subst Abus Treat. 2017 Jul 31;78:1\u20137.","journal-title":"J Subst Abus Treat"},{"issue":"9","key":"398_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2105\/AJPH.81.9.1185","volume":"81","author":"SR Yancovitz","year":"1991","unstructured":"Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991 Sep;81(9):1185\u201391.","journal-title":"Am J Public Health"},{"issue":"1","key":"398_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","volume":"63","author":"RP Schwartz","year":"2006","unstructured":"Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63(1):102\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"25","key":"398_CR27","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMc1610047","volume":"375","author":"SC Sigmon","year":"2016","unstructured":"Sigmon SC, Ochalek TA, Meyer AC, Hruska B, Heil SH, Badger GJ, et al. Interim buprenorphine vs. waiting list for opioid dependence. N Engl J Med. 2016 Dec 22;375(25):2504\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"398_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drugalcdep.2005.05.009","volume":"81","author":"WM Compton","year":"2006","unstructured":"Compton WM, Volkow ND. Major increases in opioid analgesic abuse: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"398_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra1508490","volume":"374","author":"WM Compton","year":"2016","unstructured":"Compton WM, Jones CM, Baldwin GT. Understanding the relationship between prescription opioid and heroin abuse. N Engl J Med. 2016;374:154\u201363.","journal-title":"N Engl J Med"},{"key":"398_CR30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","volume":"68","author":"RD Weiss","year":"2011","unstructured":"Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238\u201346.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"398_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/add.13238","volume":"111","author":"YI Hser","year":"2016","unstructured":"Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, et al. Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial. Addiction. 2016 Apr 1;111(4):695\u2013705.","journal-title":"Addiction"},{"key":"398_CR32","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.drugalcdep.2016.12.001","volume":"173","author":"RD Weiss","year":"2017","unstructured":"Weiss RD, Rao V. The prescription opioid addiction treatment study: what have we learned. Drug Alcohol Depend. 2017 Apr 1;173:S48\u201354.","journal-title":"Drug Alcohol Depend"},{"key":"398_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","volume":"150","author":"RD Weiss","year":"2015","unstructured":"Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015 May 1;150:112\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"398_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2016.01.003","volume":"63","author":"EL Bassuk","year":"2016","unstructured":"Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support services for addictions in the United States: a systematic review. J Subst Abus Treat. 2016 Apr 30;63:1\u20139.","journal-title":"J Subst Abus Treat"},{"key":"398_CR35","unstructured":"21st Century Cures Act, H.R. 34, 114th Cong. 2015."},{"key":"398_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0740-5472(00)00104-5","volume":"19","author":"J Hagan","year":"2000","unstructured":"Hagan J, McGough JP, Thiede J, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19:247\u201352.","journal-title":"J Subst Abuse Treat"},{"issue":"S2","key":"398_CR37","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/cid\/cit296","volume":"57","author":"NK Martin","year":"2013","unstructured":"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(S2):S39\u201345.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"398_CR38","first-page":"1496","volume":"215","author":"V Sypsa","year":"2017","unstructured":"Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, et al. Rapid decline in HIV incidence among persons who inject drugs during a fast-track combination prevention program after an HIV outbreak in Athens. J. Infect Dis. 2017;215(10):1496\u2013505.","journal-title":"Infect Dis"},{"key":"398_CR39","doi-asserted-by":"crossref","unstructured":"Dahari H, Boodram B. How to eliminate HCV in people who inject drugs in the USA. The Lancet Infectious Diseases. Available on-line: https:\/\/doi.org\/10.1016\/S1473-3099(17)30678-3 Accessed November 21, 2017.","DOI":"10.1016\/S1473-3099(17)30678-3"},{"issue":"7","key":"398_CR40","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/cid\/cit377","volume":"57","author":"J Grebely","year":"2013","unstructured":"Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention. Clin Infect Dis. 2013;57(7):1014\u201320.","journal-title":"Clin Infect Dis"},{"key":"398_CR41","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/01.aids.0000192066.86410.8c","volume":"19","author":"DC Des Jarlais","year":"2005","unstructured":"Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990\u20132001. AIDS. 2005 Oct 1;19:S20\u20135.","journal-title":"AIDS"},{"issue":"2","key":"398_CR42","doi-asserted-by":"publisher","first-page":"e87872","DOI":"10.1371\/journal.pone.0087872","volume":"9","author":"JS Montaner","year":"2014","unstructured":"Montaner JS, Lima VD, Harrigan PR, Louren\u00e7o L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV\/AIDS morbidity, mortality and HIV transmission: the \u201cHIV treatment as prevention\u201d experience in a Canadian setting. PLoS ONE. 2014;9(2):e87872. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0087872\n                      \n                    .","journal-title":"PLoS ONE"},{"key":"398_CR43","unstructured":"\u2022\u2022 Wood E. How Drug Policy Should Respond to the HIV Epidemic. Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), Vancouver, Canada, presentation TUPL0103, 2015. Policy recommendations for addressing the HIV epidemic through addressing the opioid epidemic."},{"key":"398_CR44","doi-asserted-by":"publisher","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017; \n                      https:\/\/doi.org\/10.1016\/S2214-109X(17)30373-X\n                      \n                    .","DOI":"10.1016\/S2214-109X(17)30373-X"},{"key":"398_CR45","doi-asserted-by":"publisher","unstructured":"Wu Z, Tang Z, Mao Y, Van Veldhuisen P, Ling W, Liu D, Shen Z, Detels R, Lan G, Erinoff L, Lindblad R. Testing and linkage to HIV care in China: a cluster-randomised trial. Lancet HIV 2017. doi: \n                      https:\/\/doi.org\/10.1016\/S2352-3018(17)30131-5\n                      \n                    ], 4, e555, e565.","DOI":"10.1016\/S2352-3018(17)30131-5"},{"issue":"6","key":"398_CR46","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2105\/AJPH.2011.300460","volume":"102","author":"LR Metsch","year":"2012","unstructured":"Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160\u20137.","journal-title":"Am J Public Health"},{"issue":"16","key":"398_CR47","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.2013.280034","volume":"310","author":"LR Metsch","year":"2013","unstructured":"Metsch LR, Feaster DJ, Gooden L, Schackman BR, Matheson T, Das M, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA. 2013;310(16):1701\u201310.","journal-title":"JAMA"},{"issue":"2","key":"398_CR48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2016.8914","volume":"316","author":"LR Metsch","year":"2016","unstructured":"Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016 Jul 12;316(2):156\u201370.","journal-title":"JAMA"},{"issue":"16","key":"398_CR49","first-page":"443","volume":"64","author":"C Conrad","year":"2015","unstructured":"Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone\u2014Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015 May 1;64(16):443\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"398_CR50","unstructured":"National Institute on Drug Abuse. NIDA and ARC announce funding opportunity for research projects to address opioid injection use and its consequences in the Appalachian region. 2016 Available at : \n                      https:\/\/www.drugabuse.gov\/news-events\/news-releases\/2016\/02\/nida-arc-announce-funding-opportunity-research-projects-to-address-opioid-injection-use-its\n                      \n                    . Accessed November 4, 2017."},{"key":"398_CR51","unstructured":"National Institute on Drug Abuse. Grants awarded to address opioid crisis in rural regions. 2017. Available at : \n                      https:\/\/www.drugabuse.gov\/news-events\/news-releases\/2017\/08\/grants-awarded-to-address-opioid-crisis-in-rural-regions\n                      \n                    . Accessed November 4, 2017."},{"key":"398_CR52","doi-asserted-by":"crossref","unstructured":"Crist RC, Doyle GA, Nelson EC, Degenhardt L, Martin NG, Montgomery GW, Saxon AJ, Ling W, Berrettini WH. A polymorphism in the OPRM1 3\u2032-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 2016 Dec 13.","DOI":"10.1038\/tpj.2016.89"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-018-0398-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-018-0398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-018-0398-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:26:03Z","timestamp":1562095563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-018-0398-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1007\/s11904-018-0398-8","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"3 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Wilson Compton reports long-term stock holdings in General Electric, 3M Companies and Pfizer.The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of SAMHSA, the National Institute on Drug Abuse, CDC, or the U.S. Department of Health and Human Services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}